Immunology News and Research

Latest Immunology News and Research

AANMA partners with AAE and AAPA-AAI to build network focusing on allergy, asthma care

Allergy & Asthma Network Mothers of Asthmatics, a leading patient education organization, is partnering with the Association of Asthma Educators and the American Academy of Physician Assistants in Allergy, Asthma & Immunology as part of its endeavor to build the only multidisciplinary, patient-centered network of healthcare professionals focused on allergy and asthma care.

10 Dec 2013

FDA advisory committee backs Takeda's vedolizumab for treatment of ulcerative colitis, Crohn's disease

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that a joint panel of members from the Gastrointestinal Drugs and Drug Safety and Risk Management Advisory Committees of the United States Food and Drug Administration voted to recommend approval of Takeda's vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease.

9 Dec 2013

Janssen announces first-of-its-kind pediatric HIV treatment donation program

Janssen, the pharmaceutical companies of Johnson & Johnson, today announced a first-of-its-kind pediatric HIV treatment donation program to improve access to the company's approved HIV medicines for children and adolescents failing HIV treatment in sub-Saharan Africa.

9 Dec 2013

Researchers identify central switch by which HDL controls inflammatory response

High-density lipoprotein, known colloquially as "good cholesterol", protects against dangerous deposits in the arteries. An important function of HDL is its anti-inflammatory properties. An international research team at the Institute of Innate Immunity at the University Hospital of Bonn and the LIMES Institute at the University of Bonn has identified a central switch by which HDL controls the inflammatory response. The results are presented in the current issue of "Nature Immunology".

9 Dec 2013

Genetically engineered cell therapies demonstrate early efficacy, safety in patients with blood disorders

A series of advancements in genetically engineered cell therapies demonstrate early efficacy and safety in patients with blood disorders for whom standard treatments have been unsuccessful, according to data showcased today during the 55th American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans.

9 Dec 2013

Janssen reports positive pivotal Phase 2 study data of siltuximab for Multicentric Castleman's Disease

Janssen Research & Development, LLC today announced positive results from a pivotal Phase 2 global registration study (MCD2001) suggesting siltuximab, an investigational compound, along with best supportive care, exhibited statistically significant efficacy and a tolerable safety profile compared with placebo and BSC in treating patients with the rare disorder Multicentric Castleman's Disease who are HIV-negative and human herpes virus 8-negative.

8 Dec 2013

Baylor researchers study outcomes and effectiveness of traumatic brain injury rehabilitation

For patients recovering from a traumatic brain injury (TBI), the rehabilitation process - compensating for changes in functioning, adaptation and even community reintegration - can be challenging.

6 Dec 2013

Researchers identify biomarker that may accurately predict prostate cancer spread

Researchers at Vanderbilt University Medical Center and the University of Alberta in Canada have identified a biomarker for a cellular switch that accurately predicts which prostate cancer patients are likely to have their cancer recur or spread.

6 Dec 2013

EMA expands administration options for Hizentra

CSL Behring UK Ltd announced today that the European Medicines Agency (EMA) has expanded the administration options for Hizentra®▼, human normal immunoglobulin, SCIg, 20% liquid, to include dosing once every two weeks (fortnightly).

5 Dec 2013

"Virtual T cell" predicts how human immune system reacts to foreign substances

A platform that simulates how the body defends itself: The T cells of the immune system decide whether to trigger an immune response against foreign substances.

5 Dec 2013

IDSA released new guideline for vaccination of immunocompromised hosts

A new guideline released Thursday by the Infectious Diseases Society of America (IDSA) notes that most people with compromised immune systems are especially vulnerable to illness and should receive the flu shot and other vaccinations.

5 Dec 2013

Roche signs research collaboration and licensing agreement with Molecular Partners

Roche and Molecular Partners AG today announced that they have entered into a research collaboration and licensing agreement to discover, develop and commercialize several proprietary therapeutics incorporating Molecular Partners' DARPin biologics conjugated to toxic agents developed at Roche for the treatment of cancer.

4 Dec 2013

Tackling orphan diseases: an interview with Damian Marron, CEO, TxCell

The exact definition of orphan diseases varies depending on where you are in the world. In the EU it's defined as a prevalence of less than 1 in 2,000, which equates to about 250,000 patients across the EU.

4 Dec 2013

Study focuses on effects of nanoparticles on eosinophils linked to inflammation

In a growing number of industries, workers are often unknowingly exposed to nanoparticles (NPs). Do they enter the body? Could they have an impact on health? Professor Denis Girard from the INRS-Institut Armand-Frappier Research Centre has had the foresight to study the potential toxicity of a wide variety of NPs with a view to setting the record straight before problems occur.

4 Dec 2013

Antiretroviral therapy for HIV treatment saves 2.8 million years of life in South Africa

Antiretroviral therapy for the treatment of HIV infection has saved 2.8 million years of life in South Africa since 2004 and is projected to save an additional 15.1 million years of life by 2030, according to a new study published online in The Journal of Infectious Diseases. The analysis suggests these dramatic benefits could be even greater if more aggressive HIV testing and treatment strategies are implemented.

4 Dec 2013

FDA grants QIDP status to Astellas' isavuconazole for treatment of invasive aspergillosis

Astellas Pharma US, Inc., a subsidiary of Astellas Pharma Inc. based in Tokyo, Japan, announced today that the U.S. Food and Drug Administration (FDA) designated isavuconazole as a Qualified Infectious Disease Product (QIDP) for the treatment of invasive aspergillosis.

4 Dec 2013

Top cancer research centers to establish new biotechnology company focused on cancer immunotherapy

The Fred Hutchinson Cancer Research Center (Fred Hutch) and Memorial Sloan-Kettering Cancer Center (MSKCC), along with pediatric partner Seattle Children's Research Institute, have joined forces to launch Juno Therapeutics Inc., a new biotechnology company focused on bringing forward novel immunotherapies for cancer.

4 Dec 2013

Research findings pave new ways to treat gastrointestinal disorders

For those living with gastrointestinal disorders, such as ulcers or Crohn's disease, treatment often means quelling uncomfortable symptoms through medications or dietary changes. But what if one day treatment meant doing away with the old gut for a new gut free of inflamed or diseased tissues?

4 Dec 2013

Researchers find way to replace Paneth cells with two small molecules that maintain stem cells

Researchers at MIT and Brigham and Women's Hospital have shown that they can grow unlimited quantities of intestinal stem cells, then stimulate them to develop into nearly pure populations of different types of mature intestinal cells. Using these cells, scientists could develop and test new drugs to treat diseases such as ulcerative colitis.

3 Dec 2013

Researchers offer promise of strategy for curing HIV infection

Researchers have used radioimmunotherapy (RIT) to destroy remaining human immunodeficiency virus (HIV)-infected cells in the blood samples of patients treated with antiretroviral therapy, offering the promise of a strategy for curing HIV infection. Results of the study were presented today at the annual meeting of the Radiological Society of North America (RSNA).

3 Dec 2013

Immunology News and Research

Latest Immunology News and Research

AANMA partners with AAE and AAPA-AAI to build network focusing on allergy, asthma care

FDA advisory committee backs Takeda's vedolizumab for treatment of ulcerative colitis, Crohn's disease

Janssen announces first-of-its-kind pediatric HIV treatment donation program

Researchers identify central switch by which HDL controls inflammatory response

Genetically engineered cell therapies demonstrate early efficacy, safety in patients with blood disorders

Janssen reports positive pivotal Phase 2 study data of siltuximab for Multicentric Castleman's Disease

Baylor researchers study outcomes and effectiveness of traumatic brain injury rehabilitation

Researchers identify biomarker that may accurately predict prostate cancer spread

EMA expands administration options for Hizentra

"Virtual T cell" predicts how human immune system reacts to foreign substances

IDSA released new guideline for vaccination of immunocompromised hosts

Roche signs research collaboration and licensing agreement with Molecular Partners

Tackling orphan diseases: an interview with Damian Marron, CEO, TxCell

Study focuses on effects of nanoparticles on eosinophils linked to inflammation

Antiretroviral therapy for HIV treatment saves 2.8 million years of life in South Africa

FDA grants QIDP status to Astellas' isavuconazole for treatment of invasive aspergillosis

Top cancer research centers to establish new biotechnology company focused on cancer immunotherapy

Research findings pave new ways to treat gastrointestinal disorders

Researchers find way to replace Paneth cells with two small molecules that maintain stem cells

Researchers offer promise of strategy for curing HIV infection

eBook: Cell-based technologies in drug discovery and Immunotherapy eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy